Thermo Fisher unveils mass spectrometry tools designed to speed drug development
Thermo Fisher Scientific is introducing two new mass spectrometry platforms at the American Society for Mass Spectrometry conference this week in San Diego, aiming to help researchers move discoveries from the lab into clinical trials faster.
The Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers combine hardware improvements with AI-driven software to handle the analytical demands of modern drug development, where researchers increasingly work with complex biologics like GLP-1 therapies, antibody-drug conjugates, and genetic medicines.
Discovery phase: Speed and depth
The Orbitrap Tribrid Apex targets early-stage research. It delivers five times greater sensitivity than previous instruments and can achieve 100% sequence coverage in a single experiment-meaning researchers see more of the molecular picture without running multiple tests.
Results arrive up to four times faster, allowing scientists to study cancer, neurodegeneration, and other complex diseases on one system rather than juggling multiple instruments. The platform supports over 300 research applications across proteomics, structural biology, and small-molecule analysis.
Development phase: Regulatory confidence
The Orbitrap Excedion addresses a different challenge: generating the data quality that regulatory agencies require. It detects three to five times more compounds in complex samples, catching low-abundance molecules that earlier instruments missed.
This matters for safety and efficacy decisions. Identifying critical molecular signals early reduces risk downstream and helps companies meet regulatory timelines with stronger evidence packages.
Connecting discovery to population scale
Thermo Fisher is also showcasing its Olink proteomics platform, which analyzes proteins across large patient populations. Recent software acquisitions-MSAID and Proteinaceous-add AI and machine learning capabilities to interpret complex datasets faster.
The company is applying this combination to PRECISE, a major biobank initiative in Asia studying aging and metabolic disease biomarkers.
For researchers working with AI data analysis in drug discovery, understanding how AI-enabled software interprets multiomics datasets has become essential. Those interested in the broader applications can explore AI research courses to stay current with these tools.
Your membership also unlocks:
